Showing 3,201 - 3,220 results of 5,570 for search '"Oncology"', query time: 0.09s Refine Results
  1. 3201
  2. 3202

    Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

    Published 2025-03-01
    “…Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing EGFR or ALK alterations, were aged 75 years or above, had a programmed cell death-ligand 1 tumor proportion score of less than 50%, had not undergone systemic chemotherapy, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received pemetrexed (500 mg/m2) and pembrolizumab (200 mg) on day 1 of each 21-day cycle. …”
    Get full text
    Article
  3. 3203
  4. 3204
  5. 3205
  6. 3206

    Clinical characteristics and outcomes of patients with chondroblastoma undergoing surgery with various adjuvant procedures: a retrospective study of 59 cases by Toru Hirozane, Tetsuya Sekita, Eisuke Kobayashi, Tomoaki Mori, Naofumi Asano, Toru Udaka, Takashi Tajima, Rumi Nakagawa, Kazutaka Kikuta, Akira Yoshiyama, Hideo Morioka, Itsuo Watanabe, Ukei Anazawa, Michiro Susa, Keisuke Horiuchi, Yoshihisa Suzuki, Takeshi Morii, Robert Nakayama

    Published 2025-01-01
    “…Two patients received preoperative denosumab and neither experienced local recurrence nor functional impairments. Conclusions Good oncological and functional outcomes were achieved. Age < 17 years was associated with a high risk of local recurrence after curettage (P = 0.0198). …”
    Get full text
    Article
  7. 3207
  8. 3208
  9. 3209
  10. 3210

    Preventing sensory and motor dysfunctions in children receiving neurotoxic chemotherapy: PrepAir study - an update by Céline Hammadou, Bianca Celine Schmidli, Christina Schindera, Nicolas von der Weid, Uta Tacke, Oliver Faude, Sarah Koch, Fiona Streckmann

    Published 2025-01-01
    “…This would show that specific exercise therapy is more than just a lifestyle intervention, it could be a therapy option without further side- effects, changing supportive care in oncology. References Bjornard, K. L., Gilchrist, L., Inaba, H., Diouf, B., Hockenberry, M. …”
    Get full text
    Article
  11. 3211
  12. 3212
  13. 3213
  14. 3214
  15. 3215

    Nanomédicaments pour le traitement de maladies graves et recherches duales by Couvreur, Patrick

    Published 2024-11-01
    “…Nanomedicines have made significant advances in various therapeutic areas such as oncology, infectious diseases, and several neurological disorders. …”
    Get full text
    Article
  16. 3216
  17. 3217
  18. 3218
  19. 3219
  20. 3220